CPSD2: A new approach for cyber-physical systems design and development

Autor: Sampayo, M., Peças, P.

Publikováno v: In Journal of Industrial Information Integration July 2022 28

The impact of public health crises on Lisbon public space policies: From the 19th century to the present days

Autor: Narciso, J., Sampayo, M.

Publikováno v: PROCEEDINGS OF THE 10TH WORKSHOP ON METALLIZATION AND INTERCONNECTION FOR CRYSTALLINE SILICON SOLAR CELLS.

Cities have been affected, throughout History, by earthquakes, big fires, epidemics, and pandemics that sparked moments of reflection and change in the city form and public space quantity and quality. For example, this happened after the Great Fire o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a2081cafcc85cff1977540155f15e50
https://doi.org/10.1063/5.0108435

First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

Autor: Majem, M, Sullivan, I, Viteri, S, Lopez-Vivanco, G, Cobo, M, Sanchez, JM, Garcia-Gonzalez, J, Garde, J, Sampayo, M, Martrat, G, Malfettone, A, Karachaliou, N, Molina-Vila, MA, Rosell, R

Publikováno v: EUROPEAN JOURNAL OF CANCER
r-FISABIO. Repositorio Institucional de Producción Científica
instname
European Journal of Cancer
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau

Aim of the study: The AZENT (NCT02841579) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC) and with a coexist

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0d5cc9b707e8f28dd4356b087e9b25ac
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12661

A phase II proof-of-concept study of palbociclib (P) rechallenge in patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC) and clinical benefit to prior P-based treatment (BIOPER)

Autor: Llombart-Cussac A, Cortes J, Paricio B, Gil M, Curigliano G, Perez-Garcia J, Blesa L, Borrego M, Espinosa E, Calvo L, Bermejo B, Bellet M, Todo F, de la Haba J, Quiroga V, Minisini A, Santaballa A, Sampayo M, Malfettone A, Albanell J

Publikováno v: CANCER RESEARCH
r-FISABIO. Repositorio Institucional de Producción Científica
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::bcbe30c27c4e0b88a7a1b12f0168f48b
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=12708

2273P Influence of body mass index (BMI) on the response to chemotherapy in patients with HER2+ breast cancer: Role of the leptin axis

Autor: Rodríguez, M. González, Abad, M. Fernadez, Calvo, J. Palacios, Sampayo, M., Calvo, I., Díaz, E., Míes, B. Pérez, Martínez, S. González, García, J. Pérez, Cortés, J., Moreno-Bueno, G., Estevez, L. García

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S1167-S1167